Oncoinvent ASA (ONCIN) - Net Assets
Based on the latest financial reports, Oncoinvent ASA (ONCIN) has net assets worth Nkr146.32 Million NOK (≈ $15.40 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Nkr204.96 Million ≈ $21.57 Million USD) and total liabilities (Nkr58.63 Million ≈ $6.17 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check asset allocation strategy of Oncoinvent ASA to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Nkr146.32 Million |
| % of Total Assets | 71.39% |
| Annual Growth Rate | -21.45% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 48.16 |
Oncoinvent ASA - Net Assets Trend (2021–2025)
This chart illustrates how Oncoinvent ASA's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see ONCIN market cap.
Annual Net Assets for Oncoinvent ASA (2021–2025)
The table below shows the annual net assets of Oncoinvent ASA from 2021 to 2025. Also explore Oncoinvent ASA (ONCIN) equity growth momentum to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | Nkr146.32 Million ≈ $15.40 Million |
+35.07% |
| 2024-12-31 | Nkr108.33 Million ≈ $11.40 Million |
-15.02% |
| 2023-12-31 | Nkr127.48 Million ≈ $13.41 Million |
+44.04% |
| 2022-12-31 | Nkr88.50 Million ≈ $9.31 Million |
-76.98% |
| 2021-12-31 | Nkr384.43 Million ≈ $40.45 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Oncoinvent ASA's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 15578600000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Nkr223.92 Million | 153.03% |
| Other Components | Nkr13.47 Million | 9.20% |
| Total Equity | Nkr146.32 Million | 100.00% |
Oncoinvent ASA Competitors by Market Cap
The table below lists competitors of Oncoinvent ASA ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Meta Biomed Co. Ltd
KQ:059210
|
$60.82 Million |
|
Lument Finance Trust Inc
NYSE:LFT
|
$60.83 Million |
|
W5 Solutions AB
ST:W5
|
$60.85 Million |
|
Guillemot Corporation S.A.
PA:GUI
|
$60.87 Million |
|
Savezone I C
KO:067830
|
$60.78 Million |
|
Baoye Group Company Limited
F:BKG
|
$60.78 Million |
|
Doosan Fuel Cell Co. Ltd. Pfd. Series 1
KO:33626K
|
$60.76 Million |
|
Taiwan Pelican Express Co Ltd
TW:2642
|
$60.76 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Oncoinvent ASA's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 108,334,000 to 146,324,000, a change of 37,990,000 (35.1%).
- Net loss of 155,070,000 reduced equity.
- Share repurchases of 141,000,000 reduced equity.
- New share issuances of 141,000,000 increased equity.
- Other factors increased equity by 193,060,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Nkr-155.07 Million | -105.98% |
| Share Repurchases | Nkr141.00 Million | -96.36% |
| Share Issuances | Nkr141.00 Million | +96.36% |
| Other Changes | Nkr193.06 Million | +131.94% |
| Total Change | Nkr- | 35.07% |
Book Value vs Market Value Analysis
This analysis compares Oncoinvent ASA's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.95x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 0.54x to 3.95x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | Nkr240.45 | Nkr129.00 | x |
| 2022-12-31 | Nkr733.88 | Nkr129.00 | x |
| 2023-12-31 | Nkr303.83 | Nkr129.00 | x |
| 2024-12-31 | Nkr1.17 | Nkr129.00 | x |
| 2025-12-31 | Nkr32.67 | Nkr129.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Oncoinvent ASA utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -105.98%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -552.46%
- • Asset Turnover: 0.14x
- • Equity Multiplier: 1.40x
- Recent ROE (-105.98%) is above the historical average (-161.15%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -80.47% | -39969.51% | 0.00x | 1.17x | Nkr-347.81 Million |
| 2022 | -341.39% | -77666.32% | 0.00x | 1.88x | Nkr-310.97 Million |
| 2023 | -149.36% | -53785.59% | 0.00x | 1.37x | Nkr-203.15 Million |
| 2024 | -128.57% | -16424.76% | 0.00x | 1.58x | Nkr-150.12 Million |
| 2025 | -105.98% | -552.46% | 0.14x | 1.40x | Nkr-169.70 Million |
Industry Comparison
This section compares Oncoinvent ASA's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $196,878,141
- Average return on equity (ROE) among peers: -25.55%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Oncoinvent ASA (ONCIN) | Nkr146.32 Million | -80.47% | 0.40x | $60.79 Million |
| Arcticzymes Technologies ASA (AZT) | $68.08 Million | -30.08% | 0.26x | $110.71 Million |
| Bergenbio ASA (BGBIO) | $670.23 Million | -38.35% | 0.10x | $7.75 Million |
| Circio Holding ASA (CRNA) | $-12.51 Million | 0.00% | 0.00x | $337.48 Million |
| Exact Therapeutics AS (EXTX) | $115.55 Million | -45.29% | 0.33x | $5.26 Million |
| Lytix Biopharma AS (LYTIX) | $135.13 Million | -41.45% | 0.13x | $68.78 Million |
| Nykode Therapeutics ASA (NYKD) | $23.19 Million | -6.92% | 0.08x | $130.92 Million |
| PCI Biotech Holding ASA (PCIB) | $339.95 Million | -10.23% | 0.05x | $274.95K |
| SoftOx Solutions AS (SOFTX) | $95.18 Million | -45.12% | 0.27x | $32.13 Million |
| Thor Medical ASA (TRMED) | $337.10 Million | -12.52% | 0.23x | $204.51 Million |
About Oncoinvent ASA
Oncoinvent ASA, a clinical stage company, develops radiopharmaceutical therapies against cancer. Its lead product candidate is Radspherin, an alpha-radiation therapy candidate for treating cancer that have spread to body cavities, including peritoneum in two phase 1/2a trials and one randomized phase 2 trial. The company is based in Oslo, Norway.